Responsible research & innovation (RRI) Project directory

COMPASS has compiled an overview of RRI projects and initiatives carried out in Europe over the course of the past ten years. The COMPASS project directory below contains 130 publicly funded RRI projects in Europe. Our project directory aims to facilitate the search for RRI projects in Europe. You can download search instructions here.

For a quick look at the key figures check out our factsheet. For a detailed outline, have a look at the COMPASS policy paper, which maps out approaches, objectives and thematic priorities of publicly funded RRI projects at European level, and describes their spread across Europe via budget shares and numbers of participations.

You can find more information, results and project output on responsible innovation in the European Commission’s database CORDIS, as well as the RRI Toolkit!

Over the course of the project, it has become evident that rules, regulations and funding criteria could function as external incentives to implement responsible innovation in SMEs. The Vienna University of Economics and Business (WU), as coordinator of the COMPASS project, has therefore developed recommendations for EU research and innovation policy, with support of the COMPASS High Level Expert Advisory Board.

HIVACAR

Project Acronym: HIVACAR
Project Title: Evaluating a Combination of Immune-based Therapies to Achieve a Functional Cure of HIV Infection
Funding Programme: Horizon 2020
Link: https://cordis.europa.eu/project/rcn/207437/factsheet/en
Responsible Innovation Dimension:
Description: The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4\ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.

Responsible Innovation COMPASS

Evidence and Opportunities for Responsible Innovation in SMEs

Find out more
Top